United States Patent and Trademark Office. 10,590,206 B2. United States Patent and Trademark Office. 17 Mar. 2020). PGT121 Fv* indicates the use of PGT121 Fv variants with improved manufacturing properties and nearly identical functional parameters. Fv# indicates that the anti-CD3 Fv in the Bispecific PGT121/anti-CD3 antibody was engineered in a CD3 binding and CD3 nonbinding version.(TIFF) ppat.1010467.s002.tiff (3.5M) GUID:?17937066-752C-4B47-811C-A90418F526A2 S2 Fig: Viral loads following ART initiation. Plasma viral load for 116 weeks following ART initiation. Second measurement is on day 1 following ART initiation. Dotted lines indicate limit of detection (1.7 log RNA copies per ml), values on the line were below limit of detection. Individual symbol and color coding as indicated in S1 Table.(TIFF) ppat.1010467.s003.tiff (1.1M) GUID:?6A81BB83-CD2C-4084-9BF5-A5511CA6ECA7 S3 Fig: Plasma cytokine and chemokine induction following VES administration before ART discontinuation. IL-1RA, MCP-1, MIG and I-TAC are shown on day 1 following VES administration. Data combined from all VES administrations with pre-dose levels subtracted. Red lines Mouse monoclonal to Alkaline Phosphatase indicate median values. P<0.05 for all measurement, one-way ANOVA test with Dunnett multiple-comparison correction compared with sham group. Dotted lines mark value 0.(TIFF) ppat.1010467.s004.tiff (654K) GUID:?B668DC36-A6E7-4A8A-8599-26ED28AD3969 S4 Fig: Immune cell activation following VES administration before ART discontinuation. Activation of CD4+ T cells was assessed by CD69 expression on Isradipine days 0 and 1 following VES administration. Representative data are shown following the first VES dose. Red lines indicate median values. P values calculated using two-sided Mann-Whitney tests. ns, not significant (P>0.05)(TIFF) ppat.1010467.s005.tiff (580K) GUID:?5381A97E-7663-4B50-B360-65D083F632E6 S5 Fig: ELISPOT responses in PBMCs before ART discontinuation. Gag-, Env-, and Pol-specific IFN responses are shown for each animal at week -7/-8, week 0, week 8 and week 32 as spot-forming cells (SFCs) per million PBMCs. Red lines indicate median values.(TIFF) ppat.1010467.s006.tiff (1.2M) GUID:?98E6D9F6-952C-4A8D-95BB-976EE317E799 S6 Fig: Viral DNA before discontinuation of ART. Total viral DNA in PBMCs, lymph nodes and colorectal tissue were determined by qPCR pre treatment (week -8). No difference in viral DNA between the groups for any of the tissues (P = 0.40, Isradipine P = 0.12 and P = 0.44 in PBMCs, lymph nodes and colorectal tissue, respectively, Kruskal-Wallis test). Dotted lines indicate limit of detection, values on the line were below limit of detection. Red lines indicate median values.(TIFF) ppat.1010467.s007.tiff (322K) GUID:?17F54025-D70B-4985-8A16-DD25F4F0E84F S7 Fig: Viral peak and set Isradipine point following ART discontinuation. (a) Peak and (b) set point viral loads following ART discontinuation are shown for each animal. Red lines indicate median values.(TIFF) ppat.1010467.s008.tiff (541K) GUID:?CB82A735-5726-416F-B436-26E8028E6D8E S8 Fig: ELISPOT responses in PBMCs before (week 32) and after (week 66) Isradipine ART discontinuation. (A) Gag-, Env-, and Pol-specific IFN responses are shown for each animal at week 66 as spot-forming cells (SFCs) per million PBMCs. (B) Combined Gag-, Env-, and Pol-specific IFN responses are shown for all animal, for rebounding animals and for no rebound animals at week 32 and week 66 as spot-forming cells (SFCs) per million PBMCs. (C) Combined Gag-, Env-, and Pol-specific IFN responses at week 32 (P = 0.56, Mann-Whitney test) and week 66 (P = 0.65, Mann-Whitney test) are shown for rebounding animals and for rebounding animals that resupress virus as spot-forming cells (SFCs) per million PBMCs. Isradipine Red lines indicate median values.(TIFF) ppat.1010467.s009.tiff (868K) GUID:?D36A4248-272C-4DC1-A5FE-331BF07636F3 S9 Fig: Analysis of viral rebound. Comparison of (A) pre-ART set point viral load, (B) total viral DNA in PBMCs, (C) total viral DNA in lymph nodes and (D) total viral DNA in colorectal tissue at week 32 per antibody/VES treatment group for animals that rebounded and animals that did not rebound following ART discontinuation. Dotted lines indicate limit of detection, values on the line were below limit of detection. Red lines indicate median values.(TIFF) ppat.1010467.s010.tiff (1.1M) GUID:?0437A579-D328-4FCA-B5CD-F8E49F2E38EA S10 Fig: Analysis of viral rebound and antibody exposure. Comparison of antibody exposure per antibody/VES treatment group for animals that rebounded and animals that did not rebound following ART discontinuation. Antibody exposure assessed as area under the curve (AUC). Red lines indicate median values.(TIFF) ppat.1010467.s011.tiff (314K) GUID:?38E2CDC8-A941-4BAB-8522-B52F9BFAC771 S11 Fig: CD8+ T cell depletion efficiency. CD8+ T cells per l peripheral blood are shown before and after CD8 depletion in animals with no viral rebound (n = 7, left) and in animals with viral rebound (n = 4, right) following ART discontinuation.(TIFF) ppat.1010467.s012.tiff (562K) GUID:?7A3A3B6D-ECBA-4112-B3F6-A784D1F8A08B Data Availability StatementAll relevant data are within the manuscript and its Supporting Information files. Abstract A key challenge for the development of a cure to HIV-1 infection is the persistent viral reservoir established during early infection. Previous studies using Toll-like receptor 7 (TLR7) agonists and broadly neutralizing antibodies (bNAbs) have.